Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

IAP antagonist TQB3728

An orally bioavailable, second mitochondria-derived activator of caspases (SMAC)-mimetic and an antagonist of inhibitor of apoptosis proteins (IAPs), with potential apoptosis-inducing and antineoplastic activities. Upon oral administration, IAP antagonist TQB3728 selectively targets, binds to and inhibits the activity of IAPs including X chromosome-linked IAP (XIAP) and cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This may restore and promote the induction of apoptosis through apoptotic signaling pathways and enhance proteasomal degradation of IAPs. Additionally, TQB3728 may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Smac mimetic compound TQB3728
Code name:TQB 3728
TQB-3728
TQB3728
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search